We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Swiss biotech company Idorsia has submitted a marketing authorisation application to the European Medicines Agency (EMA) for its investigational insomnia treatment daridorexant.
Idorsia Ltd and Syneos Health have formed a commercial relationship for the U.S. commercialization of Idorsia’s daridorexant, a new dual orexin receptor antagonist being investigated for the treatment of insomnia.